GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

BMY · Sep 30, 2026

BRISTOL MYERS SQUIBB CO. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]

Inspectable configuration

State dimensions

Filing0000014272-26-000024General Corporate

Debt relative to revenue25thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.debt_to_revenue

326.09% · OPTIONAL · VALID

Capex intensity70thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

2.63% · OPTIONAL · VALID

Operating cash generation65thOwn-history percentile · N=20

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

31.99% · OPTIONAL · VALID

Revenue growth75thOwn-history percentile · N=20

Evidence method

Yoy · gp.fundamentals.revenue

6.93% · CORE · VALID

Inventory pressure45thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

20.69% · OPTIONAL · VALID

Gross margin0thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.gross_margin

68.28% · CORE · VALID

R&D intensity0thOwn-history percentile · N=20

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

18.10% · OPTIONAL · VALID

SBC intensity35thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

1.06% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History4 statesSelf-history eligible

Mar 31, 20200/9 normalizedLevel 3 Jun 30, 20200/9 normalizedLevel 3 Sep 30, 20200/9 normalizedLevel 3 Sep 30, 20268/8 normalizedLevel 4

Period transition

What moved in the state?

Balance Sheet Leverage Decreased

Previous: 330.39%
Current: 326.09%
Delta: -4.29%

Capex Intensity Increased

Previous: 2.35%
Current: 2.63%
Delta: 0.28%

Cash Generation Increased

Previous: 26.15%
Current: 31.99%
Delta: 5.84%

Growth Increased

Previous: 5.74%
Current: 6.93%
Delta: 1.19%

Inventory Pressure Decreased

Previous: 21.10%
Current: 20.69%
Delta: -0.41%

Margin Decreased

Previous: 71.28%
Current: 68.28%
Delta: -3.00%

R And D Intensity Decreased

Previous: 22.81%
Current: 18.10%
Delta: -4.71%

Sbc Intensity Increased

Previous: 1.04%
Current: 1.06%
Delta: 0.02%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Dec 31, 2024

Similarity: 73%
Compared: 8 dimensions
Coverage: 100%

Growth 22.4 · Margin 10.0 · Sbc Intensity 10.0 · Capex Intensity 10.0 · Cash Generation 15.0 · R And D Intensity 60.0 · Inventory Pressure 30.0 · Balance Sheet Leverage 10.0

Dec 31, 2025

Similarity: 73%
Compared: 8 dimensions
Coverage: 100%

Growth 40.0 · Margin 5.0 · Sbc Intensity 20.0 · Capex Intensity 15.0 · Cash Generation 25.0 · R And D Intensity 45.0 · Inventory Pressure 25.0 · Balance Sheet Leverage 15.0

Jun 30, 2026

Similarity: 70%
Compared: 8 dimensions
Coverage: 100%

Growth 5.0 · Margin 15.0 · Sbc Intensity 10.0 · Capex Intensity 25.0 · Cash Generation 30.0 · R And D Intensity 70.0 · Inventory Pressure 10.0 · Balance Sheet Leverage 10.0

Jun 30, 2025

Similarity: 70%
Compared: 8 dimensions
Coverage: 100%

Growth 40.0 · Margin 10.0 · Sbc Intensity 10.0 · Capex Intensity 25.0 · Cash Generation 10.0 · R And D Intensity 50.0 · Inventory Pressure 25.0 · Balance Sheet Leverage 40.0

Dec 31, 2023

Similarity: 67%
Compared: 8 dimensions
Coverage: 100%

Growth 55.0 · Margin 47.4 · Sbc Intensity 7.1 · Capex Intensity 3.7 · Cash Generation 28.2 · R And D Intensity 36.8 · Inventory Pressure 29.2 · Balance Sheet Leverage 19.7

Research Graph

Related governed research

Analogous To · BMY state analogue 5 →Analogous To · BMY state analogue 1 →Analogous To · BMY state analogue 3 →Compared To · Pharmaceutical Preparations peers →Analogous To · BMY state analogue 4 →Analogous To · BMY state analogue 2 →Derived From · BMY Company Quality Vector →Has State · BRISTOL MYERS SQUIBB CO →Transitioned To · BMY BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · BMY CAPEX_INTENSITY_INCREASED →Transitioned To · BMY CASH_GENERATION_INCREASED →Transitioned To · BMY GROWTH_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.